Abstract
Importance The ENIGMA clinical high risk for psychosis (CHR) initiative, the largest pooled CHR-neuroimaging sample to date, aims to discover robust neurobiological markers of psychosis risk in a sample with known heterogeneous outcomes.
Objective We investigated baseline structural neuroimaging differences between CHR subjects and healthy controls (HC), and between CHR participants who later developed a psychotic disorder (CHR-PS+) and those who did not (CHR-PS-). We assessed associations with age by group and conversion status, and similarities between the patterns of effect size maps for psychosis conversion and those found in other large-scale psychosis studies.
Design, Setting, and Participants Baseline T1-weighted MRI data were pooled from 31 international sites participating in the ENIGMA CHR Working Group. MRI scans were processed using harmonized protocols and analyzed within a mega- and meta-analysis framework from January-October 2020.
Main Outcome(s) and Measure(s) Measures of regional cortical thickness (CT), surface area (SA), and subcortical volumes were extracted from T1-weighted MRI scans. Independent variables were group (CHR, HC) and conversion status (CHR-PS+, CHR-PS-, HC).
Results The final dataset consisted of 3,169 participants (CHR=1,792, HC=1,377, age range: 9.5 to 39.8 years, 45% female). Using longitudinal clinical information, we identified CHR-PS+ (N=253) and CHR-PS- (N=1,234). CHR exhibited widespread thinner cortex compared to HC (average d=-0.125, range: -0.09 to -0.17), but not SA or subcortical volume. Thinner cortex in the fusiform, superior temporal, and paracentral regions was associated with psychosis conversion (average d=-0.22). Age showed a stronger negative association with left fusiform and left paracentral CT in HC, compared to CHR-PS+. Regional CT psychosis conversion effect sizes resembled patterns of CT alterations observed in other ENIGMA studies of psychosis.
Conclusions and Relevance We provide evidence for widespread subtle CT reductions in CHR. The pattern of regions displaying greater CT alterations in CHR-PS+ were similar to those reported in other large-scale investigations of psychosis. Additionally, a subset of these regions displayed abnormal age associations. Widespread CT disruptions coupled with abnormal age associations in CHR may point to disruptions in postnatal brain developmental processes.
Question How do baseline brain morphometric features relate to later psychosis conversion in individuals at clinical high risk (CHR)?
Findings In the largest coordinated international analysis to date, reduced baseline cortical thickness, but not cortical surface area or subcortical volume, was more pronounced in CHR, in a manner highly consistent with thinner cortex in established psychosis. Regions that displayed greater cortical thinning in future psychosis converters additionally displayed abnormal associations with age.
Meaning CHR status and later transition to psychosis is robustly associated with reduced cortical thickness. Abnormal age associations and specificity to cortical thickness may point to aberrant postnatal brain development in CHR, including pruning and myelination.
Competing Interest Statement
BHE (Bjorn H. Ebdrup) is part of the Advisory Board of Eli Lilly Denmark A/S, Janssen-Cilag, Lundbeck Pharma A/S, and Takeda Pharmaceutical Company Ltd; and has received lecture fees from Bristol-Myers Squibb, Otsuka Pharma Scandinavia AB, Eli Lilly Company, Boehringer Ingelheim Danmark A/S, and Lundbeck Pharma A/S. DH (Dennis Hernaus) has received financial compensation as a consultant for P1vital Produicts Ltd. F-RM (Francisco Reyes-Madrigal) has received compensation as a speaker for Janssen (Johnson & Johnson). All reported activities were unrelated to the work presented in this manuscript.
Funding Statement
Department of Health, Australian Government | National Health and Medical Research Council (NHMRC): Ashleigh Lin 1148793 Russian Foundation for Basic Research: Alexander Tomyshev 20-013-00748 TrygFonden (Tryg Foundation): Birte Yding Glenthoj Danish Research Council: Birte Yding Glenthoj Lundbeck Foundation Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research, CIN: Birte Yding Glenthoj NHMRC Senior Research Fellowship: Barnaby Nelson 1137687 Consejo Nacional de Ciencia y Tecnologia, Mexico: Camilo de la Fuente-Sandoval 182279,261895 CONACyT's Sistema Nacional de Investigadores: Camilo de la Fuente-Sandoval NIH: Camilo de la Fuente-Sandoval R21 MH117434 NIH: Christine I Hooker R01 MH105246 Research Council of Norway: Christian K. Tamnes 288083,223273 South-Eastern Norway Regional Health Authority: Christian K. Tamnes 2019069 NIH: Cheryl Mary Corcoran R01 MH107558 NIMH: Daniel H. Mathalon R01 MH076989 Brain and Behavior Research Foundation (BBRF) Valid: Daniel H. Mathalon NIMH: Dean F Salisbury R01 MH1133533 Lundbeck Foundation: Dorte Nordholm R25-A2701,R287-2018-1485 Mental Health Services, Capital Region of Denmark: Dorte Nordholm Brain and Behaviour Research Foundation; NARSAD Young Investigator Award: Gisela Sugranyes 26731 Spanish I+D+I state program: Gisela Sugranyes ISCIII-Subdireccion General de Evaluacion: Gisela Sugranyes ERDF: Gisela Sugranyes PI18/00976 Government of Catalonia (Programa PERIS Salut Mental): Gisela Sugranyes SLT006/17/00362 Alicia Koplowitz Foundation: Gisela Sugranyes Fundacio Clinic Recerca Biomedica (Ajut a la Recerca Pons Bartran): Gisela Sugranyes National Institute for Health Research (NIHR) Maudsley Biomedical Research Centre studentship: Helen Baldwin MEC | Instituto de Salud Carlos III (ISCIII): Inmaculada Baeza INT19/00021 MEC | Instituto de Salud Carlos III (ISCIII): Inmaculada Baeza PI11/1349,PI15/0444,PI180242 Russian Foundation for Basic Research: Irina S Lebedeva 20-013-00748 NIMH: Jessica A Turner 5R01MH094524 NIH: James A. Waltz 5R01MH115031 Yong Loo Lin School of Medicine, National University of Singapore: Juan Helen Zhou National Medical Research Council Translational and Clinical Research Flagship Programme: Jimmy Lee NMRC/TCR/003/2008) Maryland Department of Health and Mental Hygiene, Behavioral Health Administration through the Maryland Center of Excellence on Early Intervention Program (MEIP), OPASS grant: Jason Schiffman 14-13717G/M00B4400241 National Research Foundation of Korea (NRF): Jun Soo Kwon 2017M3C7A1029610 National Natural Science Foundation of China (NSFC): Jinsong Tang 81871057 The University of Edinburgh: Kimberley Atkinson Japan Agency for Medical Research and Development (AMED): Kiyoto Kasai JP20dm0207069,JP20dm0307001,JP20dm0307004 NIMH: Kristen M Haut R01MH105246 Western Norway Regional Health Authority Postdoc scholarship: Ketil Oppedal 912152 Japan Agency for Medical Research and Development (AMED): Shinsuke Koike JP20dm0307001,JP20dm0207069 The Research Council of Norway: Lars Tjelta Westlye 300767 South‐Eastern Norway Regional Health Authority: Lars Tjelta Westlye 2019101 European Research Council under the European Union's Horizon 2020 research and Innovation program: Lars Tjelta Westlye 802998 Wellcome Trust: Mathew A. Harris Instituto de Salut Carlos III Fundacion Alicia Koplowitz NIMH: Maria Jalbrzikowski K01 MH112774 NIMH: Mallory J Klaunig JSPS KAKENHI: Michio Suzuki JP20H03598 Japan Agency for Medical Research and Development (AMED): Michio Suzuki JP19dk0307069s0203 Research Council of Norway: Ole Andreassen 223273,283798 KG Jebsen Stiftelsen: Ole Andreassen LifeScience Univ of Oslo: Ole Andreassen Medical Research Council: Peter PJ Uhlhaas MR/L011689/1 NIMH: Rachel L. Loewy K23MH086618; R01MH081051 H2020 ERA-NET: Inmaculada Baeza SYNSCHIZ JSPS KAKENHI: Daiki Sasabayashi JP18K15509 National Health & Medical Research Council of Australia: Stephen James Wood NIMH: Tiziano Colibazzi 5T32MH15144,K23 MH85063 Brain and Behavior Research Foundation (NARSAD): Tiziano Colibazzi Sackler Institute: Tiziano Colibazzi Herbert Irving Scholar Award: Tiziano Colibazzi Columbia University Bodini Fellowship: Tiziano Colibazzi JSPS KAKENHI: Shinsuke Koike JP18K07550 National Health & Medical Research Council of Australia: Ulrich Schall 569259 National Health & Medical Research Council (NHMRC) Investigator Grant: Vanessa Cropley 1177370 The Zurich Program for Sustainable Development of Mental Health Services (ZInEP): Wulf Rossler NIH: Romina Mizrahi R01MH100043,R01MH113564 BBF: Romina Mizrahi NATIONAL HEALTH AND MEDICAL RESEARCH COUNCIL AUSTRALIA: Alison Yung PRINCIPAL RESEARCH FELLOWSHIP
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was given by the following boards/committees: 1) Ethics Committee at University Hospital of Psychiatry, Bern 2) Research Ethics Board at the Centre for Addiction and Mental Health at the University of Toronto 3) Ethics Committee of the Second Xiangya Hospital of Central South University 4) Institutional Review Board of Columbia University 5) Ethics Committees of University of Glasgow 6) NHS Research Ethical Committee Glasgow & Greater Clyde 7) Committee on Health Research Ethics of the Capital Region Denmark 8) Danish Data Protection Agency 9) Ethics Committee of the Medical Faculty of the University of Heidelberg 10) Ethics Clinical Research Committee of the Hospital Clinic of Barcelona 11) Institute of Psychiatry Research Ethics Committee at King's College London 12) Ethics Committee of Hospital Sant Joan De Deu 13) Ethics Review Committee at Maastricht University 14) Human Research Ethics Committee at University of Melbourne 15) Ethics and Scientific Committees of the National Institute of Neurology and Neurosurgery of Mexico 16) Ethics Committee of the Mental Health Research Center, Moscow 17) Institutional Review Board at the University of Maryland School of Medicine 18)Institutional Review Board at Icahn School of Medicine at Mount Sinai 19) University of Newcastle Human Research Ethics Committee 20) Institutional Review Board of Oslo University Hospital 1) Institutional Review Board of University of Pittsburgh School of Medicine 22) Institutional Review Board of Rush University Medical Center 23) Institutional Review Board of Seoul National University Hospital 24) Ethics Committee Institute of Mental Health, Singapore 25) Medical Ethics Committee, Stavanger University Hospital 26) Committee on Medical Ethics at Toho University 27) Institutional Review Board at the University of California, San Francisco 28) Research Ethics Committee of the Faculty of Medicine of the University of Tokyo 29) Committee on Medical Ethics at Toyama University 30) Research Ethics Review Committee at Vrije Universiteit Amsterdam 31) Ethic Commission Zurich
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
We corrected the name for Montserrat Dolz
Data Availability
All code used in this project is publicly available here: https://osf.io/p9ntr/ Due to individual site IRB restrictions, data is not publicly available. Please contact the ENIGMA CHR Working Group co-chairs if you are interested in joining and participating in the working group. Then you will be able to submit secondary data proposals.
